Research and Clinical Trials on Citalopram (Celexa, Cipramil, Seropram)

Citalopram (Celexa, Cipramil, Seropram) Clinical Research Trials

From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Citalopram (Celexa, Cipramil, Seropram).

• Responses of Myocardial Ischemia to Escitalopram Treatment
  Status: Recruiting, Condition Summary: Myocardial Ischemia
• Lexapro in the Treatment of Patients With Postpartum Depression
  Status: Completed, Condition Summary: Postpartum Depression
• Efficacy and Safety of Escitalopram Doses up to 50mg in Treatment of MDD
  Status: Recruiting, Condition Summary: Major Depressive Disorder
• Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women
  Status: Completed, Condition Summary: Depression; Depressive Disorder; Depressive Disorder, Major
• Citalopram in Treating Postmenopausal Women With Hot Flashes
  Status: Active, not recruiting, Condition Summary: Breast Cancer; Cancer-Related Problem/Condition
• Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder
  Status: Recruiting, Condition Summary: Anxiety Disorders; Somatoform Disorders
• Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline
  Status: Recruiting, Condition Summary: Breast Cancer; Cancer-Related Problem/Condition
• Flushing in Social Anxiety Disorder on Cipralex
  Status: Not yet recruiting, Condition Summary: Social Anxiety Disorder
• Citalopram in Irritable Bowel Syndrome
  Status: Recruiting, Condition Summary: Irritable Bowel Syndrome
• Augmenting Antidepressant Treatment With Interpersonal Psychotherapy for Treating Late-Life Depression
  Status: Active, not recruiting, Condition Summary: Depression
• Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-Uptake Inhibitor (SSRI)
  Status: Recruiting, Condition Summary: Alcoholism; Alcohol Abuse
• The Effect of Escitalopram on the Pharmacokinetics and Pharmacodynamics of Tramadol in Healthy Subjects
  Status: Completed, Condition Summary: Healthy
• Treatment of Post-Traumatic Stress Disorder With High Doses of Escitalopram
  Status: Enrolling by invitation, Condition Summary: Stress Disorders, Post Traumatic
• Ramelteon for Sleep Initiation Insomnia in Individuals With Panic Disorder Who Are Also on Escitalopram for Anxiety
  Status: Recruiting, Condition Summary: Panic Disorder; Insomnia
• Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression
  Status: Recruiting, Condition Summary: Depression

 

Get These Clinical Trials as a Newsfeed

Citalopram:             

Current Research Literature on Citalopram (Celexa, Cipramil, Seropram)

Here are abstracts for some of the latest research articles to have appeared on Citalopram (Celexa, Cipramil, Seropram):

Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules.

Int J Cardiol. 2008 Nov 10;
Lekakis J, Ikonomidis I, Papoutsi Z, Moutsatsou P, Nikolaou M, Parissis J, Kremastinos DT
BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) exert cardioprotective effects. We examined whether SSRIs a) modulate endothelial cell expression of vascular cell adhesion molecule (VCAM-1), intracellular adhesion molecule (ICAM-1) and adhesiveness to U937 monocytes, b) reduce the circulating levels of these adhesion molecules in vivo. METHODS: We assessed the effect of SSRIs, (citalopram, fluvoxamine and fluoxetine), on TNF-alpha-induced expression of VCAM-1 and ICAM-1 in human aorta endothelial cells and adhesiveness to U937 monocytes. Cells were incubated with TNF-alpha in the absence and in the presence of SSRIs concentrations from 10(-7) M to10(-4) M and the VCAM-1 and ICAM-1 expression was quantified by cell-ELISA. The TNF-alpha-stimulated adhesiveness to U937 monocytes was also assessed. Twenty five patients with chronic heart failure and depression were randomized to receive sertaline 50 mg, p.o., o.d. (n=13) or placebo. At baseline and 3-months after treatment, we measured VCAM-1and ICAM-1 plasma levels. RESULTS: SSRIs decreased the TNF-alpha-induced endothelial expression of VCAM-1 at concentration range 10(-7) M to 10(-4) M (p

Depressant-like effects of parthenolide in a rodent behavioural antidepressant test battery.

J Pharm Pharmacol. 2008 Dec; 60(12): 1643-50
Pandey DK, Rajkumar R, Mahesh R, Radha R
The anti-serotonergic effects of parthenolide (PTL) demonstrated in platelets inspired the present psychopharmacological investigation, which employs a battery of rodent behavioural assays of depression. In mice, PTL (0.5-2 mg kg(-1)) exhibited dose-dependent depressant-like effects in a forced swim test and a tail suspension test, without affecting the baseline locomotor status. The doses (1 and 2 mg kg(-1)) that induced depressant-like effects were found to significantly reduce 5-hydroxytryptophan-induced head twitch response. Interaction studies revealed that the depressant-like effects of PTL (1 mg kg(-1)) were reversed more efficiently by serotonergic antidepressants (venlafaxine, escitalopram, citalopram, fluoxetine) than by others (desipramine, bupropion) tested. Chronic treatment of PTL (1 and 2 mg kg(-1)) augmented the hyper-emotionality of olfactory bulbectomized rats, when compared with sham rats, as observed in modified open field, elevated plus maze and social interaction paradigms. This study depicts the severe depressogenic potential of PTL (in its pure form) plausibly mediated by platelet/neuronal hypo-serotonergic effects.

Remission of maternal depression: relations to family functioning and youth internalizing and externalizing symptoms.

J Clin Child Adolesc Psychol. 2008 Oct; 37(4): 714-24
Foster CE, Webster MC, Weissman MM, Pilowsky DJ, Wickramaratne PJ, Talati A, Rush AJ, Hughes CW, Garber J, Malloy E, Cerda G, Kornstein SG, Alpert JE, Wisniewski SR, Trivedi MH, Fava M, King CA
Family functioning and parenting were hypothesized to mediate the relation between remission of maternal depression and children's psychosocial adjustment. Participants were 114 mother-child dyads participating in the Sequenced Treatment Alternatives to Relieve Depression Child 3-month follow-up. All mothers had been diagnosed with major depressive disorder and were treated initially with citalopram; 33% of mothers experienced remission of depressive symptoms. Youth ranged in age from 7 to 17. Remission of maternal depression was associated with changes in children's reports of their mothers' warmth/acceptance, which in turn partially mediated the relation between maternal depression remission and youth internalizing symptoms, accounting for 22.9% of the variance.

Pharmacotherapy in restorative neurology.

Curr Opin Neurol. 2008 Dec; 21(6): 639-43
Liepert J
PURPOSE OF REVIEW: To evaluate current evidence that recovery after stroke or traumatic brain injury (TBI) can be enhanced by drugs that modulate neurotransmission in the brain. RECENT FINDINGS: Small studies performed in chronic stroke patients have indicated that single doses of reboxetine or citalopram improved different aspects of motor functions and that long-lasting application of donepezil reduced aphasic symptoms. Methylphenidate shortened intensive care treatment periods in TBI patients and amantadine improved arousal and cognition. Recent studies in stroke patients did not find beneficial effects of levodopa or dextroamphetamine. SUMMARY: Evidence of drug-related improvement of functions after stroke or TBI is still limited, either because of small and highly selected patient groups or due to conflicting results. Currently, most convincing evidence exists for piracetam for improvement of poststroke aphasia and amantadine for enhancing arousal and cognition after TBI. Some evidence can be found for improvement of stroke-related motor deficits by levodopa, enhanced speed of mental processing in TBI by methylphenidate and improvement of poststroke aphasia by dextroamphetamine. Large randomized controlled trials are needed to evaluate the effectiveness of serotonin reuptake inhibitors or noradrenaline reuptake inhibitors on motor functions.

Screening and semiquantitative analysis of drugs and drugs of abuse in human serum samples using gas chromatography-mass spectrometry.

Neuro Endocrinol Lett. 2008 Oct 11; 29(5): 749-754
Maresova V, Chadt J, Novakova E
OBJECTIVES: The purpose of this study is to develop the gas chromatographicmass spectrometric method (GC-MS) for screening and semiquantification of drugs and drugs of abuse in human serum. METHOD: GC-MS method after liquid-liquid extraction (LLE) and derivatization with N-methyl-Ntrimethylsilyltrifluoroacetamide (MSTFA) is presented for screening as well as identification and semiquantification of the most frequently used drugs and drugs of abuse in human serum. RESULTS: Bovine serum spiked with ephedrine (EPHE), 3,4-methylenedioxymethamphetamine (MDMA), guaifenesin (GUAIF), tramadol (TRAM), phenobarbital (PHENO), amitriptyline (AMITR), cocaine (COCA), mirtazapine (MIRTA), dothiepin (DOTH), citalopram (CITAL), clomipramine (CLOMI), bromazepam (BMZPM), diazepam (DZPM), codeine (COD), morphine (MORPH), levomepromazine (LEVO), zolpidem (ZOLP), clozapine (CLOZP), alprazolam (ALPZM) was used for the recovery and repeatability study and for preparation of calibration curves of individual compounds or their TMS derivatives. Recoveries were tested on concentration levels 0.05, 0.1 and 0.5 mug/mL (n=6) and established in range 72.0-98.0%. Repeatabilities expressed as relative standard deviations (RSDs) measured at concentration levels 0.05, 0.1 and 0.5 mug/ mL (n=6) were lower than 10.0%. The calibration curves for analytes or their TMS derivatives were linear in concentration range 0.025-2.000 mug/mL (except EPHE 2TMS, MDMA TMS, MORPH 2TMS, BMZPM TMS, ALPZM) with correlation coefficients exceeding 0.99. The limit of quantification (LOQ) for analytes used for evaluation study was 0.025 mug/mL (except analytes mentioned above). CONCLUSIONS: The GC-MS method presented here is allowing screening, identification and semiquantification of the most commonly encountered drugs and drugs of abuse in human serum and can be successfully applied to analysis of real samples from clinical and forensic toxicology cases.